Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib alone or with pembrolizumab in previously untreated KRAS G12C-mutant advanced or metastatic non-small cell lung cancer
CTR20233972Phase 2Active
- Sponsor
- Roche
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of divarasib and pembrolizumab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Roche. Started Jan 2024; status: active.
02
Drugs
divarasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20233972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233972.